Sinobiopharma, Inc.


Headquartered in Nanjing, China, Sinobiopharma (OTCBB: SNBP) is a vertically integrated, research-driven specialty pharmaceutical company founded in 2004. Known as Dong Ying (Jiangsu) Pharmaceutical Co. Ltd. in China, the company is engaged in R&D, manufacturing, marketing and distribution of biopharmaceutical products, with a primary focus on the muscle relaxant and heart disease areas. By using its innovative methods of active pharmaceutical ingredient (“API”) synthesis and drug delivery, the company intends to introduce products that enhance usability, reduce drug development timelines and costs. Sinobiopharma has successfully brought four drugs to the Chinese market, including its flagship product, KuTai (cisatracurium), a leading muscle relaxant and its recently launched product, YiTai (perindopril), a first-to-market cardiovascular ACE inhibitor. The company has an additional four candidates in the pipeline. Sinobiopharma’s production facilities are GMP-certified by the China State Food and Drug Administration (SFDA) and the company has an established distribution network in China.

Recent News


2 Huangpu Road,
Nanjing, Jiangsu Province 210000,
People's Republic of China